TRanslational Initiative to DE‐risk NeuroTherapeutics (TRIDENT) – A revolutionary pre‐clinical approach to maximize the predictive validity of pre‐clinical evaluation
This will transform the current approaches of pre-clinical testing in neurodegenerative disorders, making the process attractive to pharmaceutical and biotechnology industries to find effective cures and therapies.
Authors
- Joel C. Watts (ORCID: https://orcid.org/0000-0002-2604-2925)
- Ali R. Khan (ORCID: https://orcid.org/0000-0002-0760-8647)
- Thomas M. Durcan (ORCID: https://orcid.org/0000-0003-3942-1956)
- Justine Cléry (ORCID: https://orcid.org/0000-0003-1020-1845)
- Edward A. Fon (ORCID: https://orcid.org/0000-0002-5520-6239)
- Vânia F. Prado (ORCID: https://orcid.org/0000-0003-4994-6393)
- E. Richard Gold (ORCID: https://orcid.org/0000-0002-3789-9238)
- Liisa A.M. Galea (ORCID: https://orcid.org/0000-0003-2874-9972)
- Sriram Jayabal (ORCID: https://orcid.org/0000-0002-0485-6725)
- Jaqueline Sullivan
- Timothy J. Bussey (ORCID: https://orcid.org/0000-0002-3180-3709)
- Mallar Chakravarty
- Lisa M Saksida
- Marco AM Prado
- Ravi S. Menon
Institutions
- Western University (CA)
- Montreal Neurological Institute and Hospital (CA)
- Centre for Addiction and Mental Health (CA)
- University of Toronto (CA)
- McGill University (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_104027
- Primary Topic
- Pluripotent Stem Cells Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00